The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index, and 1 are not checked yet.
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Open accessAbstract
Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all “maybe” abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A meta-analysis reported 31%–73% of breast cancer survivors are adherent to AET,10”
From Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: Protocol for a pilot fractional factorial trial (2023) · cites this paper as [10]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of barriers to medication use have been reported in this setting, including medication side-effects, psychological distress and a lack of social support [4, 15].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Non -adherence to adjuvant endocrine therapy (AET) in women with breast cancer is common and associated with medication side -effects and distress.”
The cited source says what the claim attributes to it.
In the citing paper
“Adherence to adjuvant endocrine therapy is affected by medication side-effects and associated distress.”
The cited source says what the claim attributes to it.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
The cited source says what the claim attributes to it.
In the citing paper
“Non-adherence to AET is a major problem among women with breast cancer [4]”
In the citing paper
“Despite these benefits, between 31-73% of survivors discontinue adjuvant hormonal therapy in clinical practice,6 thereby reducing treatment efficacy.7-10”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, few interventions have been developed to improve adjuvant hormonal therapy adherence.6”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Patient variables (e.g., age), social support, patient-provider communication, and healthcare factors (e.g., cost) have been associated with breast cancer survivor adherence to systemic therapies.6, 16-18”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, adherence to hormonal therapy is suboptimal.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“While hormonal treatment related side effects such as hot flashes and osteoporosis42 represent one of the main reasons for discontinuation,6 none of the retrieved interventions had an explicit focus on side effects.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Although studies have shown that adherence is problematic in both older and younger women similarly,6 the reasons for discontinuation or barriers to adherence may be different between the two groups.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Tamoxifen for early breast cancer: an overview of the randomised trials
Abe, O., Bartholomeus, S., & Piccart, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,180
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
From Cancer Patient to Cancer Survivor: Lost in Transition
(2005) · PsycEXTRA Dataset · doi:10.1037/e720092007-001 · Cited by 2,364
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Research works printed but not linked: 1
- Salgado BA, Zivian MT (2006) Aromatase inhibitors: side effects reported by 622 women. Breast Cancer Res Treat 100:S1618
Cited by
Sorted by citations
Items 401–500 of 710
Seibert, T. A., Shi, L., Althouse, S. K., Hoffman, R. L., Schneider, B. P., Russ, K. A., Altherr, C. A., Warden, S. J., Guise, T. A., Coggan, A. R., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-51751-y · Cited by 7
Kuo, C., Wang, H., & Tseng, L. M. (2021) · Nursing Open · doi:10.1002/nop2.963 · Cited by 8
Park, C., Heo, J., Mehta, S., Han, S., & Spencer, J. C. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01247-w · Cited by 7
Vizin, G., Szekeres, T., Juhász, A., Marton, L., Dank, M., Perczel-Forintos, D., & Urbán, R. (2023) · BMC Psychology · doi:10.1186/s40359-023-01355-4 · Cited by 10
Sbaity, E., Tamim, H., Fuleihan, G. E., Abbas, J., Zahwe, M., Sayed, R. E., & Shamseddine, A. I. (2024) · BMC Cancer · doi:10.1186/s12885-024-11910-w · Cited by 7
Mokbel, K., Weedon, M. N., Moye, V., & Jackson, L. M. (2024) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20461 · Cited by 7
Adachi, Y., Oze, I., Sawaki, M., Hattori, M., Yoshimura, A., Kotani, H., Kataoka, A., Sugino, K., Horisawa, N., Ozaki, Y., et al. (2021) · Breast Cancer · doi:10.1007/s12282-021-01245-w · Cited by 7
Adherence to oral hormonal anticancer agents in breast cancer
Gori, S., Modena, A., Foglietta, J., Verzè, M., Inno, A., Casarin, A., Russo, A. D., & Nicolis, F. (2022) · Tumori Journal · doi:10.1177/03008916221096183 · Cited by 7
Bluethmann, S. M., Flores, E. S., Grotte, M., Heitzenrater, J., Truica, C. I., Olsen, N. J., Sciamanna, C., & Schmitz, K. H. (2022) · Journal of Aging and Physical Activity · doi:10.1123/japa.2022-0013 · Cited by 7
Self-citationYan, Y., Fu, J., Gu, Z., Lu, J., Su, Y.-J., & Lin, H. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01450-3 · Cited by 7
Rodin, D. L., Sutradhar, R., Jerzak, K. J., Hahn, E., Nguyen, L., Castelo, M., Fatiregun, O. A. A., Fong, C. H., Mata, D. G. M. M., Trebinjac, S., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06989-x · Cited by 7
Tamoxifen Benefits and CYP2D6 Testing in Women With Hormone Receptor-Positive Breast Cancer
Kaplan, M., & Mahon, S. M. (2013) · Clinical journal of oncology nursing · doi:10.1188/13.cjon.174-179 · Cited by 7
The Experience of Initiating Oral Adjuvant Treatment for Estrogen Receptor–Positive Breast Cancer
Flanagan, J. M., Tetler, D., Winters, L. N., Post, K. E., & Habin, K. R. (2016) · Oncology nursing forum · doi:10.1188/16.onf.e143-e152 · Cited by 7
Bedi, J. S., Mayo, R. M., Truong, K. D., Chen, L., Dickes, L., Sherrill, W. W., & Jones, K. O. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4866-z · Cited by 8
Kim, Y., Min, Y. H., & Lee, S. B. (2020) · Health Care For Women International · doi:10.1080/07399332.2020.1802460 · Cited by 7
Green, S. M. C., French, D., Hall, L., Bartlett, Y. K., Rousseau, N. S., Raine, E., Parbutt, C., Gardner, B., ROSETA Investigators, & Smith, S. G. (2023) · Journal of Medical Internet Research · doi:10.2196/38073 · Cited by 7
Eraso, Y. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s211939 · Cited by 7
Sebaoun, P., Marchal, F., Weryha, G., Hamdaoui, S. E., Salleron, J., & Lesur, A. (2019) · Bulletin du Cancer · doi:10.1016/s0007-4551(20)30050-3 · Cited by 7
Şendur, M. A. N., Aksoy, S., Zengin, N., & Altundağ, K. (2013) · PubMed · Cited by 7
Adesão à Terapia Hormonal Adjuvante com Tamoxifeno e Anastrozol utilizando ARMS-12 e MMAS-4
de Botelho, L. O., Sañudo, A., Facina, G., & Wagner, G. A. (2022) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2022v68n2.1960 · Cited by 6
Arch, J. J., Slivjak, E. T., Bright, E. E., Crespi, C. M., Levin, M. E., Genung, S. R., Nealis, M. S., ALBRIGHT, K. J., Mitchell, J. L., Sheth, A. D., et al. (2022) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2022.07.002 · Cited by 6
van den Biggelaar, Y., Kuiper, J. G., van der Sangen, M. J. C., Luiten, E. J. T., Siesling, S., van Herk‐Sukel, M. P. P., Voogd, A. C., & Mesters, I. (2023) · Breast Disease · doi:10.3233/bd-230024 · Cited by 6
Pagan, E., Ruggeri, M., Bianco, N., Bucci, E. O., Graffeo, R., Borner, M., Giordano, M., Gianni, L., Rabaglio, M., Freschi, A., et al. (2024) · The Breast · doi:10.1016/j.breast.2024.103765 · Cited by 6
Piazzon, N., Cortet, M., Vérot, E., & Carrouel, F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104548 · Cited by 6
Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial
Hammarström, M., Gabrielson, M., Bergqvist, J., Lundholm, C., Crippa, A., Bäcklund, L. M., Wengström, Y., Borgquist, S., Eliasson, E., Eriksson, M., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae280 · Cited by 6
Jong, A. D., von Wachenfeldt, A., Nyström, L., & Andersson, A. (2024) · Acta Oncologica · doi:10.2340/1651-226x.2024.40575 · Cited by 6
van Nijnatten, R. Y. M., Buijs, S. M., Agema, B. C., Fischer, R. M. J., Moghaddam-Helmantel, I. M. G., Contant, C. M. E., de Jongh, F. E., Huijben, A. M. T., Kop, M., van der Padt‐Pruijsten, A., et al. (2025) · The Breast · doi:10.1016/j.breast.2025.103880 · Cited by 6
Assad, D. X., dos Santos, D. L., Resende, H. M., Moura, F., Oliveira, S. C. S., Shimada, A. K., Arakelian, R., Galvão, A. L. Z., de Souza, B. S. W., Custódio, A. G. C., et al. (2025) · JCO Global Oncology · doi:10.1200/go-24-00351 · Cited by 6
Graetz, I., Hernandez, S., Hu, X. Y., Krukowski, R. A., Anderson, J. N., Waters, T. M., Stepanski, E. J., Vidal, G. A., & Schwartzberg, L. S. (2025) · The Breast · doi:10.1016/j.breast.2025.104552 · Cited by 6
Harrell, M., Fabbri, D., & Levy, M. A. (2017) · JCO Clinical Cancer Informatics · doi:10.1200/cci.16.00044 · Cited by 6
Effects of Exercise on Cancer Treatment Completion and Efficacy
Morielli, A. R., & Courneya, K. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-42011-6_10 · Cited by 6
Tamoxifen treatment adherence assessment by women with breast cancer
Rangel, C. O., Colet, C. D. F., Bandeira, V. A. C., Gelatti, G. T., Salazar, R. F. D. S., & Horn, R. C. (2020) · Revista de Epidemiologia e Controle de Infecção · doi:10.17058/jeic.v10i1.13314 · Cited by 6
Laws, A., Cheifetz, R. E., Warburton, R., McGahan, C. E., Pao, J., Kuusk, U., Dingee, C. K., Quan, M. L., & McKevitt, E. C. (2020) · Current Oncology · doi:10.3747/co.27.6515 · Cited by 6
Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?
Beltran-Bless, A.-A., Vandermeer, L., Ibrahim, M. F. K., Hutton, B., Shorr, R., Savard, M.-F., & Clemons, M. J. (2021) · Current Oncology · doi:10.3390/curroncol28040229 · Cited by 6
Beisel, C., Poretta, T., Sheppard, V. B., de Mendoza, A. H., Sipsma, H. L., Fuqua, E., Stwalley, B. D., Salvatore, A., & Yang, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02221-2 · Cited by 6
Walsh, E. A., Post, K. E., Massad, K., Horick, N., Antoni, M. H., Penedo, F. J., Safren, S. A., Partridge, A. H., Peppercorn, J. M., Park, E. R., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07228-z · Cited by 6
Murphy, C. C., Tiro, J. A., Jean, G. W., Balasubramian, B. A., & Álvarez, C. A. (2017) · Journal of Women s Health · doi:10.1089/jwh.2016.6099 · Cited by 6
Self-citationWimmer, T., Ortmann, O., Gerken, M., Klinkhammer‐Schalke, M., Koelbl, O., & Inwald, E. C. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-018-5030-z · Cited by 6
Impact of patients’ refusal to undergo adjuvant treatment measures on survival
Männle, H., Siebers, J. W., Momm, F., & Münstedt, K. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05939-1 · Cited by 6
Sharifi, G., Alavi, E., Haddadian, K., Rezaee, O., Ali-Asgari, A., & Faramarzi, F. (2012) · PubMed · Cited by 6
Green, S. M. C., Hall, L., Rousseau, N. S., French, D., Graham, C. D., Collinson, M., Mason, E. D., Wilkes, H., Howdon, D., Foy, R., et al. (2023) · NIHR Open Research · doi:10.3310/nihropenres.13337.2 · Cited by 6
Adherence Rates and Correlates in Long-term Hormonal Therapy
Dunn, J., & Gotay, C. C. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-416673-8.00003-4 · Cited by 7
Emanuel, G., Henson, K. E., Broggio, J., Charman, J., Horgan, K. J., Dodwell, D. J., & Darby, S. C. (2019) · Cancer Epidemiology · doi:10.1016/j.canep.2019.04.012 · Cited by 6
The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence
Neuner, J. M., Fergestrom, N. M., Laud, P. W., Nattinger, A. B., Beyer, K. M. M., Flynn, K. E., & Pezzin, L. E. (2019) · Cancer · doi:10.1002/cncr.32433 · Cited by 6
Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review
Fleshner, N. E., Alibhai, S. M. H., Connelly, K. A., Martins, I., Eigl, B. J., Lukka, H. R., & Aprikian, A. G. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231152845 · Cited by 6
Tamoxifen therapy for patients with breast cancer
Huiart, L., Ferdynus, C., & Giorgi, R. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61235-0 · Cited by 6
Xing, P., Dong, H., Liu, Q., Yao, F., Xu, Y., Chen, B., Zheng, X., Wu, Y., Jin, F., & Li, J. (2017) · Oncotarget · doi:10.18632/oncotarget.18454 · Cited by 6
Jacobsen, P. B., & Snyder, C. F. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2110 · Cited by 6
Eriksson, L., Matikas, A., Liu, X., & Foukakis, T. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103493 · Cited by 6
Marano, G., Paris, I., Traversi, G., Mazza, O., Pavese, F., D’Angelo, T., Franceschini, G., & Mazza, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041574 · Cited by 5
Edmonds, M. C., Dahman, B. A., Kim, S. J., McGuire, K. P., & Sheppard, V. B. (2023) · BMC Women s Health · doi:10.1186/s12905-023-02246-x · Cited by 5
Chan, W., Wong, Y.-L., Tai, Y.-C., Liu, X., Yun, B., Zhang, Y., Hou, H. L.-Y., Kwong, D. L. �., Lee, V. H.-F., & Lam, W. (2024) · Cancers · doi:10.3390/cancers16234084 · Cited by 5
Kostov, A. M., Jensen, M., Ejlertsen, B., Thomassen, M., Rossing, M., Pedersen, I. S., Petersen, A. H., Christensen, L. L., Wadt, K., Berrocal-Almanza, L. C., et al. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07726-2 · Cited by 5
Family ties: young breast cancer patients and their children
Güth, U., Huang, D. J., Alder, J., & Moffat, R. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14163 · Cited by 5
Kelly, B. N., Kantor, O., Tang, R., Coopey, S. B., Smith, B. L., Lanahan, C. R., Korotkin, J. E., & Specht, M. C. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-06026-1 · Cited by 5
Development of health behaviour questionnaire for breast cancer women in Mainland China
Xu, H., Jiang, G., Zhang, X., Wang, D., Xu, L., & Wang, A. (2020) · Nursing Open · doi:10.1002/nop2.737 · Cited by 5
Edmonds, M. C., Kim, S. J., Wells, M., Dahman, B. A., & Sheppard, V. B. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.08.009 · Cited by 6
Zheng, D., & Thomas, J. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06992-2 · Cited by 5
Quality of Decision Making in Radiation Oncology
Vinod, S. K., Merie, R., & Harden, S. (2024) · Clinical Oncology · doi:10.1016/j.clon.2024.02.001 · Cited by 5
Medication use by early-stage breast cancer survivors: a 1-year longitudinal study
Loh, K. Y., Ng, T. R. D., Lee, C. P., Ng, R. C.-H., & Chan, A. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2950-z · Cited by 7
Application status of tamoxifen in endocrine therapy for early breast cancer
Hu, Q., Luo, T., Zhong, X., He, P., Tian, T., & Zheng, H. Y. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2437 · Cited by 5
Güth, U., Huang, D. J., Schötzau, A., & Schmid, S. M. (2015) · Oncology · doi:10.1159/000439570 · Cited by 5
Felder, T. M., Phuong, D., Lu, K., Lal, L. S., Heiney, S. P., & Bennett, C. L. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3803-2 · Cited by 5
Yin, Z., Warner, J. L., & Malin, B. (2018) · Europe PMC (PubMed Central) · Cited by 5
Felder, T. M., Heiney, S. P., Hébert, J. R., Friedman, D. B., Elk, R. A., Franco, R., Gansauer, L. J., Christensen, B., & Ford, M. E. (2020) · JMIR Research Protocols · doi:10.2196/17742 · Cited by 5
Haskins, C., McDowell, B. D., Carnahan, R. M., Fiedorowicz, J. G., Wallace, R. B., Smith, B. J., & Chrischilles, E. A. (2020) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2020.110294 · Cited by 5
Wei, M., Wang, X., Zimmerman, D. N., Burt, L., Haaland, B. A., & Henry, N. L. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-06071-w · Cited by 5
Mueller‐Schoell, A., Klopp‐Schulze, L., Michelet, R., van Dyk, M., Mürdter, T. E., Schwab, M. G., Joerger, M., Huisinga, W., Mikus, G., & Kloft, C. (2021) · Pharmaceuticals · doi:10.3390/ph14020115 · Cited by 5
Tsai, C.-J., Huang, H., Chen, F., Yang, Y., Chen, L., & Hsieh, K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262934 · Cited by 5
Ni, C., Warner, J. L., Malin, B., & Yin, Z. (2022) · PubMed · Cited by 6
AlOmeir, O., Patel, N., & Donyai, P. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-07435-2 · Cited by 5
Foldi, J., Tsagianni, A., Salganik, M., Schnabel, C. A., Brufsky, A., Londen, G. J. V., Pusztai, L., & Sanft, T. B. (2023) · BMC Cancer · doi:10.1186/s12885-023-11104-w · Cited by 5
Johnsson, A. (2015) · SOJ Nursing & Health Care · doi:10.15226/2471-6529/1/1/00102 · Cited by 5
Coscia, E. B., Sabha, M., Gerenutti, M., Groppo, F. C., & Bergamaschi, C. D. C. (2017) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0036-1597974 · Cited by 5
Zaibet, S., Vauchier, C., Khoudour, N., Dugage, M. R., Korb‐Savoldelli, V., Alexandre, J., Blanchet, B., Goldwasser, F., Thomas‐Schoemann, A., & Bellesœur, A. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.08.005 · Cited by 5
Choi, J., Park, C. S., Seong, M.-K., Seol, H., Kim, J., Park, I., Noh, W. C., & Kim, H. (2020) · Journal of Breast Cancer · doi:10.4048/jbc.2020.23.e5 · Cited by 5
Montagna, E., Pagan, E., Bagnardi, V., Colleoni, M. A., Cancello, G., Munzone, E., Dellapasqua, S., Bianco, N., Campennì, G. M., Iorfida, M., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05900-2 · Cited by 6
Perceptions of Endocrine Therapy in African-American Breast Cancer Survivors: Mixed Methods Study
Donevant, S. B., Heiney, S. P., Wineglass, C. M., Schooley, B. L., Singh, A., & Sheng, J. (2021) · JMIR Formative Research · doi:10.2196/23884 · Cited by 5
Moyad, M. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-23422-9_7 · Cited by 5
Okroša, A. D., Silovski, T., Plavetić, N. D., Silovski, H., Kovačić, A., & Mucalo, I. (2023) · Acta Pharmaceutica · doi:10.2478/acph-2023-0043 · Cited by 4
Li, H., Song, G., Xiao, B., & Gong, Q. (2024) · Psycho-Oncologie · doi:10.18282/po3599 · Cited by 4
Smith, S. G., Green, S. M. C., McNaught, E., Graham, C. D., Foy, R., Ow, P. L., French, D., Hall, L., Wilkes, H., Ba, C. T., et al. (2025) · Annals of Behavioral Medicine · doi:10.1093/abm/kaaf003 · Cited by 5
Murphy, C. C., Fullington, H. M., Gerber, D. E., Bowman, I. A., Puligandla, M., Dutcher, J. P., DiPaola, R. S., & Haas, N. B. (2021) · Cancer Medicine · doi:10.1002/cam4.4140 · Cited by 4
Self-citationHeer, S. E., Tromp, V. N. M. F., Westerman, M. J., Konings, I. R. H. M., Beckeringh, J. J., Boons, C. C. L. M., Timmers, L., & Hugtenburg, J. G. (2022) · European Journal of Cancer Care · doi:10.1111/ecc.13749 · Cited by 7
Zheng, D., & Thomas, J. (2023) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2023.101599 · Cited by 4
Aurell, C., Haidar, A., & Giglio, D. (2024) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234241240171 · Cited by 4
O’Reilly, D., Farooq, A. R., Selvadurai, P. N., Sheehan, L., Molan, K., Krishnanivas, B., Mullen, V., McMahon, D. J., Hadi, D. K., Ahmed, A., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae146 · Cited by 4
McGee, S. F., Clemons, M. J., Pond, G. R., Caudrelier, J.-M., Liu, M., Alzahrani, M. J., Ng, T. L., Awan, A. A., Sehdev, S. R., Hilton, J. F., et al. (2024) · Current Oncology · doi:10.3390/curroncol31080338 · Cited by 4
Ghosh, R., Pfeiffer, R. M., Roberts, S., Gierach, G. L., & Dallal, C. M. (2024) · Cancer Causes & Control · doi:10.1007/s10552-024-01900-5 · Cited by 4
“When Less is More”: Paradigm Shifts in Radiation Treatment for Early-Stage Breast Cancer
Rhodes, S. S., Miller, D. G., & Chino, F. L. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01253-w · Cited by 4
Li, H., Liu, C., Ke, S., Cui, L., Sun, M., Bian, Y., Song, Y., & Lü, Q. (2025) · Asia-Pacific Journal of Oncology Nursing · doi:10.1016/j.apjon.2025.100701 · Cited by 4
Freidlin, B., Abrams, J. S., & Korn, E. L. (2013) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.13.50 · Cited by 4
Aromatase inhibitors: The unexpected breast cancer treatment
Pieters, H. C., Green, E., Sleven, M., & Stanton, A. L. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.07.024 · Cited by 4
Bîlc, M. I., Pollmann, N., Buchholz, A., Lauche, R., & Cramer, H. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08603-2 · Cited by 4
Karmakar, M. (2013) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 4
Kalder, M., Ziller, V., Kyvernitakis, I., Knöll, D., Hars, O., & Hadji, P. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1402-8 · Cited by 4
Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model
Andrade, F. D. O., Yu, W., Zhang, X., Carney, E., Hu, R., Clarke, R. C., Fitzgerald, K. T., & Hilakivi-Clarke, L. A. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0393 · Cited by 4
Lesur, A., Dalenc, F., & Beguignot, M. (2019) · Bulletin du Cancer · doi:10.1016/s0007-4551(20)30045-x · Cited by 5
Green, S. M. C., Graham, C. D., Collinson, M., Ow, P. L., Hall, L., French, D., Rousseau, N. S., Wilkes, H., Taylor, C., Raine, E., et al. (2024) · Translational Behavioral Medicine · doi:10.1093/tbm/ibae066 · Cited by 3
Carraça, E. V., Rodrigues, B., Franco, S. F., Nobre, I., Jerónimo, F., Ilharco, V., Silva, P. F., Palmeira, A. L., & Silva, M. N. (2026) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/s12966-026-01873-5 · Cited by 3
Metadata
- Authors
- Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Murphy, Caitlin C.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2012-06-12
- Volume
- 134
- Issue
- 2
- Pages
- 459-478
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- PMC
- PMC3607286
- OpenAlex
- W1987753117
- Semantic Scholar
- 92816b1cff05e88d3955bfa52d7d9c9f3eafb040
- Cited by
- 708
- References
- 85
- Citations by year
- 2026: 32 · 2025: 63 · 2024: 59 · 2023: 67 · 2022: 71 · 2021: 59 · 2020: 60 · 2019: 54 · 2018: 41 · 2017: 64 · 2016: 33 · 2015: 38 · 2014: 32 · 2013: 34 · 2012: 1
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R25CA057712, R01CA112223, K07CA140159)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- adjuvant endocrine therapy, breast cancer survivors, medication adherence, treatment persistence, tamoxifen, aromatase inhibitors, hormone receptor-positive breast cancer, out-of-pocket costs, treatment side effects, behavioral interventions
- MeSH terms
- Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Neoplasms, Hormone-Dependent, Chemotherapy, Adjuvant, Survivors, Antineoplastic Agents, Hormonal, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
